Study shows antibody therapy clears Alzheimer's plaques in mice

December 5, 2012, Cell Press

Antibodies against amyloid beta (Aβ) protein deposits that are thought to play a role in Alzheimer's disease have shown some success in preventing the buildup of deposits in animals, but they have not been effective at removing preexisting deposits. Now researchers reporting in the December issue of the Cell Press journal Neuron show that a modified antibody was able to clear preexisting Aβ deposits in a mouse model of Alzheimer's disease.

"These findings have important implications for current and future development of antibodies for the treatment of Alzheimer's disease," says first author Ronald DeMattos, PhD, of and Company.

One of the hallmarks of Alzheimer's disease is the accumulation between of hard, insoluble called amyloid plaques (or deposits). These plaques consist of Aβ fragments that are normally broken down and eliminated in the healthy brain. Emerging literature suggests that extensive plaque occurs in Alzheimer's disease patients some 10 years prior to first memory complaint, and by the time of diagnosis, plaque deposition is already reported to be at or near maximal levels.

Immunotherapy for Alzheimer's disease is a promising that uses antibodies to target and clear Aβ that exists as a soluble peptide or within insoluble deposits. Thus far, many investigators have utilized antibodies that can bind both soluble and insoluble forms of Aβ. These antibodies are effective in reducing amyloid deposition in mice prone to developing plaques, when given as a preventative measure; however, when given to aged mice with preexisting plaques, they have little or no effect and often cause severe side effects.

Dr. DeMattos and his colleagues hypothesized that these are unable to remove existing plaques because they become saturated with soluble Aβ when they enter the brain, and as such they are not able to bind to their intended target. To test this hypothesis, they developed a genetically engineered antibody that selectively targets the plaques.

The Lilly researchers found that their plaque-specific antibody crossed the blood-brain barrier, bound to deposited beta amyloid, and caused robust clearance of preexisting plaques in mice without causing microhemorrhage. A comparator antibody that bound to both soluble and insoluble Aβ did not effectively lower existing plaques yet caused an increase in microhemorrhage. "The data suggest that an antibody that binds to only insoluble amyloid beta is likely critical for plaque removal without the associated adverse event of microhemorrhage," says Dr. DeMattos.

The Lilly researchers believe these results are consistent with their original hypothesis. "Target engagement is fundamental for the clearance of deposited plaques, and these results highlight that approaches aimed at increasing antibody binding, or target engagement, will result in significant plaque clearance," says Dr. DeMattos.

The findings may help explain why the Alzheimer's drug bapineuzumab was no better than placebo in two recent late-stage trials in patients who had mild to moderate Alzheimer's disease. Bapineuzumab binds to both soluble and insoluble beta amyloid.

Explore further: Clue to cause of Alzheimer's dementia found in brain samples

More information: DeMattos et al.: "A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice." DOI: 10.1016/j.neuron.2012.10.029

Related Stories

Clue to cause of Alzheimer's dementia found in brain samples

October 22, 2012
Researchers at Washington University School of Medicine in St. Louis have found a key difference in the brains of people with Alzheimer's disease and those who are cognitively normal but still have brain plaques that characterize ...

New research dashes notions of benign brain plaque

May 22, 2012
(Medical Xpress) -- The time may have come to scrub the idea that brain plaque — deposits of protein that clog passages between brain cells — might not be all that bad.

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.